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a b s t r a c t
Labile iron, i.e. iron that is weakly bound and is relatively unrestricted in its redox activity, has been
implicated in both the pathogenesis as well as treatment of cancer. Two cancer treatments where labile
iron may contribute to their mechanism of action are pharmacological ascorbate and ionizing radiation
(IR). Pharmacological ascorbate has been shown to have tumor-speciﬁc toxic effects due to the formation
of hydrogen peroxide. By catalyzing the oxidation of ascorbate, labile iron can enhance the rate of
formation of hydrogen peroxide; labile iron can also react with hydrogen peroxide. Here we have
investigated the magnitude of the labile iron pool in tumor and normal tissue. We also examined the
ability of pharmacological ascorbate and IR to change the size of the labile iron pool. Although a
signiﬁcant amount of labile iron was seen in tumors (MIA PaCa-2 cells in athymic nude mice), higher
levels were seen in murine tissues that were not susceptible to pharmacological ascorbate. Pharmaco-
logical ascorbate and irradiation were shown to increase the labile iron in tumor homogenates from this
murine model of pancreatic cancer. As both IR and pharmacological ascorbate may rely on labile iron for
their effects on tumor tissues, our data suggest that pharmacological ascorbate could be used as a radio-
sensitizing agent for some radio-resistant tumors.
& 2013 The Authors. Published by Elsevier B.V. All rights reserved.
Introduction
Iron is an essential redox active metal used to catalyze many
chemical reactions within organisms. The principal catalytic activity
of iron is the facilitation of electron transfer between different
biomolecules. Within the active site of enzymes, iron catalyzes
many essential bio-reactions. In general, iron within these enzymes
is sterically, thermodynamically, and kinetically restricted so that
electron transfer only occurs between desired reactants. Although
the majority of cellular iron is found within proteins, there is a
small, transient pool of weakly bound iron within cells that is not
restricted in its catalytic activity and can therefore aid in the
transfer of electrons to unwanted targets, such as dioxygen, result-
ing in the formation of oxidative species [1]. This iron is referred to
as labile iron or the labile iron pool (LIP) [2,3]. As it is weakly bound,
this iron can be chelated by compounds such as deferrioxamine
(Desferals, DFO) and is thus also referred to as the chelatable iron
pool [2,4]. Although the properties of having unrestricted redox
activity and being chelatable are not necessarily mutually inclusive,
here we assume that the magnitude of the labile iron pool is
proportional to that of the chelatable iron pool.
The oxidations initiated by labile iron can result in damage to
proteins, lipids, and DNA. DNA damage brought about by labile
iron has been proposed to be involved in the pathogenesis of
various cancer [5–7]. This pool of iron has been estimated to be
less than 5% of the total iron within cells; in hepatocytes this pool
is estimated as 1% [3,8] with intracellular concentrations being
0.2–5 mM [4–11]. Although small, this subset of iron is biologically
signiﬁcant as only very small amounts of catalytic metals are
needed to initiate oxidation cascades [12,13].
Along with playing a role in the development of cancer, labile
iron also has therapeutic relevance in cancer. Many cancer thera-
pies rely in the catalytic activity of iron to form oxidative species.
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For example, bleomycin requires iron to form oxidative species
that damage DNA [14]; labile iron is the likely the source of
this iron.
There is renewed interest in the use of high dose, pharmaco-
logical ascorbate (high plasma levels, 4E20 mM in plasma) in
the treatment of many different types of cancer [15–19]. Pharma-
cological ascorbate has been shown to selectively kill cancer cells
via the extracellular formation of hydrogen peroxide [15,20–23].
Catalytic metals can accelerate the oxidation of ascorbate [24],
leading to a greater ﬂux of H2O2 and thereby increase its toxicity.
Catalytic metals, such as labile iron, can also react with hydrogen
peroxide, forming the very damaging hydroxyl radical via the
Fenton reaction, [25],
Fe2þþH2O2-Fe3þþOHþHO
thereby increasing the oxidative stress initiated by pharmacologi-
cal ascorbate. In fact, Lipinski et al. showed that in murine
lymphoma cell lines the size of the labile iron pool correlated
with cellular susceptibility to pharmacological ascorbate [11].
We propose that catalytic iron is important to the cytotoxic
effects of pharmacological ascorbate. Therefore, in order to under-
stand the mechanism by which pharmacological ascorbate can be
selectively toxic to cancer cells, one must look at the labile iron
pool. The labile iron pool can increase in size via the release of iron
from ferritin, the main storage protein of iron, in response to
oxidative stress [26,27]. Thus, changes in the magnitude of the
labile iron pool in oxidatively stressed and oxidatively non-
stressed states are of great interest. Since catalytic metals can
enhance the oxidation of ascorbate, both the magnitude of the
labile iron pool, as well as the change of the labile iron pool could
be major determinants of the susceptibility of cells to pharmaco-
logical ascorbate. Both AscH and IR have been known to cause
the release of iron from ferritin [28,29]. In fact, chelation of this
iron has been shown to be protective against the oxidative stress
caused by IR [30].
Pharmacological ascorbate has been shown to sensitize cells to
IR [31–33]. As redox active iron plays a central role in both the
mechanisms of pharmacological ascorbate and IR, we hypothe-
sized that the combination of IR and ascorbate will increase the
labile iron pool to a greater extent than either modality alone.
In this study we measured the labile iron pool of pancreatic tumor
xenografts grown in murine models, and compared it to non-
neoplastic murine tissue. We also investigated the change in the
labile iron pool caused by treatment with pharmacological ascor-
bate with and without IR.
Materials methods
Materials
Phosphate buffered saline (PBS) was made from laboratory
reagents using Nanopures Type 1 water; all buffers were treated
with Chelexs 100 (Sigma, C7901) to remove adventitious metals [34].
Desferal (DFO, Sigma) 1 M stock solutions were made with
Nanopures Type 1 water. Ferritin from equine spleen was pur-
chased from Sigma Chemical Co., St. Louis, MO (F4503). Before use,
horse spleen ferritin was placed in dialysis tubing and suspended
overnight in Nanopures water containing EDTA to remove loosely
bound iron.
Cell culture
The human pancreatic cancer cell lines MIA PaCa-2 were used
in this study. They were purchased from American type culture
collection (ATCC) and passaged for fewer than six months after
receipt. DMEM was supplemented with 10% fetal bovine serum,
100 U/mL penicillin and 100 μg/mL streptomycin to make 500 mL
medium for growing MIA PaCa-2 cells at 37 1C humidiﬁed atmo-
sphere containing 5% CO2.
Tumor xenografts and treatments
Athymic nude mice were obtained from Harlan Laboratories
(Indianapolis, IN). The nude mice protocol was reviewed and
approved by the Animal Care and Use Committee of The University
of Iowa and was in compliance with The U.S. Public Health Service
Policy on Humane Care and Use of Laboratory Animals (NIH). MIA
PaCa-2 cells (2106) were injected s.c. with a 1-mL tuberculin
syringe equipped with a 25-gauge needle into the hind legs of
30-day old mice. Tumors and other tissues were harvested from the
mice when the tumors reached 1000 mm3. Harvested tumors and
murine tissues were stored at 80 1C or immediately processed.
Tumors or tissues were homogenized using a mortar and
pestle, with 2 mL of pH 6.5 PBS per mg of wet tissue weight. DFO
(10 mM stock solution) was then added to achieve a ﬁnal con-
centration of 1 mM DFO. Tumor homogenates were incubated
with DFO on ice for 1 h, unless otherwise noted.
Prepared samples in 4 mm O.D. EPR tubes (Wilmad-LabGlass,
Vineland, NJ, 707-SQ-250M; for this analytical work a set of tubes
was selected such that each had the same characteristics and i.d.)
were ﬂash frozen in liquid nitrogen. The samples were analyzed
for labile iron using electron paramagnetic resonance (EPR; Bruker
EMX EPR spectrometer), monitoring the signal of the high spin
ferrioxamine (Fe3þ–DFO) at g¼4.3 at 100 K (using the Bruker
ER4111VT variable temperature accessory) with the following EPR
instrument parameters: center ﬁeld 1575 G, sweep width 500 G,
typical microwave frequency 9.766 GHz, power 20 mW, receiver
gain 2105, modulation frequency 100 kHz, modulation ampli-
tude 2 G, time constant 163.84 ms, conversion time 20.48 ms,
resolution 1024 points, and number of scans 5. Use of the variable
temperature accessory allowed signal-averaging with the rela-
tively weak signals from samples with low levels of ferrioxamine.
All samples were analyzed three times; each time the sample was
removed from the EPR cavity and then repositioned within the
cavity before initiating spectral scans. The median signal intensity
(A.U.) from the triplicate measures was used to determine the
labile iron concentration of the samples in conjunction with a
standard curve.
Ferrioxamine (Fe3þ Desferals) standards were made using
ferrous sulfate and phosphate-buffered saline, pH 6.5. DFO
(1 mM) was added and then standard samples were incubated
overnight at room temperature to ensure that all of the iron was
chelated by DFO. Standards were ﬂash frozen in liquid nitrogen
and analyzed by EPR using identical procedures and instrument
settings as the tissue samples. Multiple standards of the same
concentration were made and analyzed for quality control. Final
concentrations of ferrioxamine in the standards ranged from 1.0 to
15.0 μM. A linear response of signal intensity vs. [ferrioxamine]
was obtained with correlation coefﬁcients of Z0.98.
IR was delivered from a 137Cs source in the Ionizing Radiation
Services Facility at The University of Iowa. Freshly harvested
tumors were cut into halves with one half to receive IR and the
other serving as control. Tumor halves were then homogenized
and analyzed for labile iron as above.
To determine how ascorbate would modulate the labile iron
pool, tumors were grown, harvested and homogenized as above
without incubation on ice. Each homogenate was split into two
aliquots with one treated with AscH (10 mM) and the other with
saline. Both aliquots were incubated at 37 1C for 4 h and analyzed
for labile iron using EPR as above.
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To determine how ascorbate with IR would modulate the labile
iron pool in tumors homogenates were split into 4 aliquots: one
received no treatment, the second received 10 mM AscH , the
third received 15 Gy IR, and the last received 10 mM AscH and
15 Gy IR. Samples were incubated on ice for 1 h and analyzed for
labile iron as above.
For the experiments with ferritin, samples of 50 mM ferritin;
50 mM ferritin with 1 mM DFO; and 50 mM ferritin with 1 mM DFO
and 10 mM AscH were incubated at room temperature for 24 h
and then analyzed using EPR for labile iron as above.
Results
Labile iron is present in tumors
Labile iron is a subset of the total pool of intracellular iron. In
general it is iron that is weakly bound and redox active. Its
concentration is highly variable between different cells and
tissues. It has been demonstrated that a higher level of labile iron
correlates with susceptibility to H2O2, and a possible increased
susceptibility to pharmacological ascorbate [11]. Therefore, we
examined the magnitude of the labile iron pool in tumor tissue
and compared to normal murine tissues. While a signiﬁcant
amount of labile iron was found in tumors of the MIA PaCa-2
xenograph model for pancreatic cancer (Avg. 1771 mmol kg1
E17 mM, n¼37), larger amounts of labile iron were found in
normal murine tissues, Table 1 and Fig. 1, with the highest levels
detected in the pancreas (62 mmol kg1 E62 μM). In general,
these levels in whole tissue homogenates are higher than previous
reports of the level of the intracellular LIP, E0.2–10 μM [4,9,11].
Since our study examines whole tissue, the mechanical processing
of tissues may affect this pool. In addition, the release of proteases
could lead to some additional release of iron.
As expected, we also observed that murine liver had high levels
of chelatable iron. Liver is known to have a high iron content,
E400 μmol kg1 [35]. The level of chelatable iron in liver deter-
mined here is roughly 6% of the total liver iron content. The level
of the intracellular LIP in hepatocytes has been estimated to be on
the order of 1% of total iron [4].
Ascorbate induces the release of iron from ferritin in vitro
Pharmacological ascorbate has been shown to release iron from
ferritin [36]. Thus, to fully understand the role of labile iron in the
cytotoxic actions of pharmacological ascorbate, one must look at
potential sources of labile iron, such as ferritin. Solutions of 50 μM
ferritin, 50 μM ferritin with 1 mM DFO, and 50 μM ferritin with
1 mM DFO and 10 mM AscH were incubated at room tempera-
ture for 24 h and then analyzed for labile iron by EPR. Pharmaco-
logical ascorbate caused a signiﬁcant release of iron from ferritin,
Table 2 and Fig. 2. Under these experimental conditions, it is
estimated that approximately 10 irons were released from each
ferritin molecule, i.e. 0.3% of the iron stored in ferritin, assuming
the ferritin was saturated containing E4500 ions of iron per
molecule of ferritin [27]. Cell lines have been shown to be 8–
15 μM ferritin [37]; this would indicate that the amount of iron
released into the intracellular labile iron pool would be on the
order of 100 μM. Ferritin is only one of the possible sources for
labile iron, but could be the principal source under these
conditions.
Ascorbate increases the labile iron pool in tumor homogenates
Since pharmacological levels of ascorbate may increase the
labile iron pool due to release of iron from sources such as ferritin,
we next examined tumor homogenates to see if a parallel change
in the labile iron pool could be observed. Tumor homogenates
incubated with AscH (10 mM), a plasma level easily achieved
with pharmacological AscH therapy [19,38], had a larger labile
iron pool, Fig. 3. The average labile iron concentration of the
AscH-treated group was 32 μM, compared to that of the control
Table 1
Chelatable iron levels in tumor and murine tissue homogenatesa.
Meanb Medianb Std error n
Tumor 17 15 1 37
Lung 21 17 4 6
Muscle 24 24 2 6
Spleen 30 23 9 3
Heart 33 36 5 6
Kidney 38 34 4 6
Liver 50 41 20 6
Pancreas 62 62 3 4c
a MIA PaCa-2 tumors grown in nude athymic mice were harvested along with
murine tissues. Tumors and tissues were homogenized in 2 mL of pH 6.5 PBS per mg
of wet weight, after which 1 mM DFO was added. Tissues were incubated on ice for
1 h and analyzed for labile iron using EPR at g¼4.3 and 100 K.
b Micromoles (μmol) of chelatable iron per kg wet weight of tissue. Assuming a
density of 1 g mL1, this would be concentration in units of μM.
c Due to their small size, two pancreata were pooled for a sample. Therefore,
although the total of pancreata used was 4, only two samples were available for
examination by EPR.
Fig. 1. Chelatable iron is present in tissues. Levels of chelatable iron in tissues are
determined by EPR detection of ferrioxamine. Tissues were homogenized with 2 μL
of PBS pH 6.5 per mg of wet weight, then 1 mM DFO was immediately added.
Samples were incubated on ice for 1 h and then analyzed using EPR at g¼4.3 at
100 K. Means are shown. Error bars represent standard error.
Table 2
Iron release from ferritin in vitroa.
Ferritin
(50 μM)
Ferritin
(50 μM)þDFO
(1 mM)
Ferritin (50 μM)þDFO
(1 mM)þAscH (10 mM)
[Fe3þ-DFO] (μM) 15 250 760
Moles of
chelatable iron
in sample
7.3109 1.3107 3.8107
Percent of iron
released
NAb NAb 0.3c
a All solutions were incubated at room temp for 24 h. The solution was then
ﬂash frozen in liquid nitrogen and analyzed for labile iron using EPR at g¼4.3 at
100 K. Concentrations were determined using a standard curve. Kinetically and
thermodynamically, DFO will chelate all of the iron released from ferritin.
The reverse process was assumed to be negligible.
b Not applicable.
c The percent of iron released assumed that a saturated ferritin molecule holds
4500 atoms of iron.
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group having 23 μM (p¼0.008), a 40% increase under these experi-
mental conditions.
Post mortem IR has no effect on the magnitude of the labile iron pool
IR is another cancer treatment modality that is dependent on
labile iron for some portion of its cytotoxic actions [30]. IR of
tissues produces free radicals; the primary radicals produced by IR
can lead to secondary radical formation that can be enhanced via
labile iron; free radical-mediated oxidations can increase the labile
iron pool [28]. Therefore, we looked at the ability of IR to modulate
the labile iron pool in harvested tumors. MIA PaCa-2 tumors
grown in mice were harvested and bisected. Post mortem IR of
tumors had no effect on the labile iron pool, Fig. 4. Of the 11
tumors that were irradiated, ﬁve irradiated halves had a larger
labile Iron pool than their non-irradiated counter parts and six did
not. The average labile iron concentration for all irradiated tumor
halves was 1670.7 mM and for non-irradiated halves it was
1771.2 mM, essentially identical (p¼0.28). In order to understand
these results, tumor halves, both of which received no IR, were
analyzed via the same method to look at the homogeneity of labile
iron within tumors, Fig. 5. The labile iron concentration of the
tumors varied. The average difference in the concentration of
labile iron in these tumor halves was 3.871.1 mM. This is similar to
the average difference of the tumor halves of which one received IR
and one did not, 3.170.7 mM. Thus, there is no apparent increase in
labile iron from IR under these experimental conditions.
Ascorbate and IR increase labile iron
Pharmacological ascorbate has been shown to sensitize tissues
to IR [32,33]. Since iron can both potentiate the formation of free
radicals and the free radicals formed via IR can increase the labile
iron pool, the radio-sensitizing effects could in part be due to an
increase in labile iron. The ability of IR to alter the labile iron pool
in an oxygenated tumor homogenate was investigated with and
without co-treatment with pharmacological ascorbate. Both IR or
pharmacological ascorbate alone show a possible trend to an
increased labile iron pool in tumor homogenates, p¼0.23 and
0.19, respectfully, Fig. 6. However, our data suggest an apparent
additive effect with the combined treatment of AscH and
irradiation, p¼0.06.
Fig. 2. Ascorbate releases iron from ferritin in vitro. Solutions of 50 mM ferritin;
50 mM ferritin and 1 mM DFO; or 50 mM ferritin, 1 mM DFO with 10 mM ascorbate
were made using pH 6.5 PBS. Samples were incubated at room temperature for
24 h and analyzed for labile iron using EPR at g¼4.3 and 100 K.
Fig. 3. Ascorbate increases the amount of labile iron in tumor homogenates. MIA
PaCa-2 cells were grown in nude athymic mice. Tumors were harvested and
homogenized in 2 mL of pH 6.5 PBS per mg wet weight, then 1 mM DFO was
immediately added. Each tumor homogenate was split into two samples: one to
serve as the control and one to receive 10 mM AscH. Samples were incubated at
37 1C for 4 h and analyzed three separate times for labile iron using EPR at g¼4.3
and 100 K. Values represent the median in units of mmol (kg wet weight)1. Error
bars represent the standard error. p¼0.008 for control vs. treated with AscH .
Fig. 4. Post mortem whole tissue irradiation does not alter labile iron levels. MIA
PaCa-2 tumors grown in 11 different nude athymic mice were harvested and
bisected with one half to receive radiation and one to serve as a control. Tumors
were immediately irradiated with 15 Gy while the control halves were stored
under similar conditions. Both halves were homogenized in 2 mL of pH 6.5 PBS per
mg wet weight, then 1 mM DFO was immediately added. Samples were incubated
on ice for 1 h and analyzed three separate times using EPR at g¼4.3 and 100 K.
Values represent the median value of three separate analyses of the same sample.
Error bars represent the standard error. p¼0.28 for control vs. treated with AscH .
Fig. 5. The concentration of labile iron is non-homogenous within tumors. MIA
PaCa-2 tumors grown in athymic nude mice were harvested and bisected
(randomly). Each half was homogenized in 2 mL of pH 6.5 PBS per mg wet weight,
then 1 mM DFO was immediately added. Samples were incubated on ice for 1 h and
then analyzed using EPR at g¼4.3 and 100 K. Values represent the median value of
three separate analyses of the same sample. The variation for the three measures of
each sample was small, parallel to Figs. 3 and 4.
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Discussion
Labile iron may play an important role in the mechanism of
action of pharmacological ascorbate, both in catalyzing the oxida-
tion of ascorbate to generate a ﬂux of H2O2 and in the potentiation
of oxidative damage through activation of H2O2. The release of
labile iron from sources such as ferritin in vivo by high levels of
ascorbate could contribute to the effectiveness of pharmacological
ascorbate as an adjuvant in cancer therapy. In certain cells, the size
of the labile iron pool has been correlated with the sensitivity of
cells to pharmacological ascorbate [11]. However, our data show
normal murine tissues have a larger labile iron pool than
ascorbate-sensitive tumors. Thus, the varying ability of cells to
handle the ﬂux of H2O2 produced by pharmacological ascorbate is
also a prime consideration [22,39]. Our results on whole tissue
show higher levels of labile iron than previously reported intra-
cellular levels, which could be due in part to the mechanical
disruption of the tissues.
We examined the ability of IR to increase the labile iron pool in
tumors. Irradiation of post mortem whole tumor tissue showed no
change in the labile iron pool. However, irradiation of tumor homo-
genates resulted in an increase in the labile iron pool. This may be due
in part to the availability of oxygen; secondary radical formation from
IR will be greatly diminished in hypoxic tissue reducing the potential
for the release of labile iron. The tumor tissue post mortem will
undoubtedly be hypoxic, whereas the homogenized tissue will be
partially oxygenated, contributing to the ability of IR to release labile
iron. If the increase in labile iron contributes to the toxicity of both
ascorbate and radiation alone as well as in combination, pharmaco-
logical ascorbate could be used to increase the radio-sensitivity of
many different types of tumors. These results also suggest that iron-
targeted anti-neoplastic agents may be more effective when combined
with pharmacological ascorbate.
Acknowledgments
This research was supported by NIH Grant R01 CA169046, U01
CA166800, R01 GM073929, and the Medical Research Service of
the Department of Veterans Affairs 1I01BX001318. We thank the
Holden Comprehensive Cancer Center (P30 CA086862) for an
Oberley Seed Grant as well as support of Core facilities. The
content is solely the responsibility of the authors and does not
represent views of the National Institute of Health.
References
[1] S.Y. Qian, G.R. Buettner, Iron and dioxygen chemistry is an important route to
initiation of biological free radical oxidations: an electron paramagnetic
resonance spin trapping study, Free Radic. Biol. Med. 26 (1999) 1447–1456.
[2] F. Petrat, H. de Groot, R. Sustmann, U. Rauen, The chelatable iron pool in living
cells: a methodically deﬁned quantity, Biol. Chem. 383 (2002) 489–502.
[3] B.P. Espósito, S. Epsztejn, W. Breuer, Z.I. Cabantchik, A review of ﬂuorescence
methods for assessing labile iron in cells and biological ﬂuids, Anal. Biochem.
304 (1) (2002) 1–18.
[4] Y. Ma, H. de Groot, Z. Liu, R.C. Hider, F. Petrat, Chelation and determination of
labile iron in primary hepatocytes by pyridinone ﬂuorescent probes, Biochem.
J. 395 (1) (2006) 49–55.
[5] M. Glei, G.O. Latunde-Dada, A. Klinder, T.W. Becker, U. Hermann, K. Voigt,
B.L. Pool-Zobel, Iron-overload induces oxidative DNA damage in the human
colon carcinoma cell line HT29 clone 19A, Mutat. Res. 519 (2002) 151–161.
[6] J. Jian, Q. Yang, J. Dai, J. Eckard, D. Axelrod, J. Smith, X. Huang, Effects of iron
deﬁciency and iron overload on angiogenesis and oxidative stress-a potential
dual role for iron in breast cancer, Free Radic. Biol. Med. 50 (2011) 841–847.
[7] W.H. Ibrahim, H.M. Habib, H. Kamal St, D.K. Clair, C.K. Chow, Mitochondrial
superoxide mediates labile iron level: evidence from Mn-SOD-transgenic mice
and heterozygous knockout mice and isolated rat liver mitochondria, Free
Radic. Biol. Med. 65 (2013) 143–149.
[8] S. Epsztejn, H. Glickstein, V. Picard, I.N. Slotki, W. Breuer, C. Beaumont,
Z.I. Cabantchik, H-ferritin subunit overexpression in erythroid cells reduces
the oxidative stress response and induces multidrug resistance properties,
Blood 94 (1999) 3593–3603.
[9] W. Breuer, S. Epsztejn, Z.I. Cabantchik, Dynamics of the cytosolic chelatable
iron pool of K562 cells, FEBS Lett. 382 (3) (1996) 304–308.
[10] A.M. Konijn, H. Glickstein, B. Vaisman, E.G. Meyron-Holtz, I.N. Slotki,
Z.I. Cabantchik, The cellular labile iron pool and intracellular ferritin in K562
cells, Blood 94 (1999) 2128–2134.
[11] P. Lipinski, J.C. Drapier, L. Oliveira, H. Retmanska, B. Sochanowicz,
M. Kruszewski, Intracellular iron status as a hallmark of mammalian cell
susceptibility to oxidative stress: a study of L5178Y mouse lymphoma cell lines
differentially sensitive to H2O2, Blood 95 (2000) 2960–2966.
[12] J. Vasquez-Vivar, B. Kalyanaraman, M.C. Kennedy, Mitochondrial aconitase is a
source of hydroxyl radical. An electron spin resonance investigation, J. Biol.
Chem. 275 (19) (2000) 14064–14069.
[13] G.R. Buettner, Ascorbate autoxidation in the presence of iron and copper
chelates, Free Radic. Res. Commun. 1 (1986) 349–353.
[14] D.H. Petering, R.W. Byrnes, W.E. Antholine, The role of redox-active metals in
the mechanism of action of bleomycin, Chem. Biol. Interact. 73 (1990)
133–182.
[15] J. Du, S.M. Martin, M. Levine, B.A. Wagner, G.R. Buettner, S.H. Wang,
A.F. Taghiyev, C. Du, C.M. Knudson, J.J. Cullen, Mechanisms of ascorbate-induced
cytotoxicity in pancreatic cancer, Clin. Cancer Res. 16 (2) (2010) 509–520.
[16] M.G. Espey, P. Chen, B. Chalmers, J. Drisko, A.Y. Sun, M. Levine, Q. Chen,
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of
pancreatic cancer, Free Radic. Biol. Med. 50 (11) (2011) 1610–1619.
[17] J. Du, J.J. Cullen, G.R. Buettner, Ascorbic acid: chemistry, biology and the
treatment of cancer, Biochim. Biophys. Acta—Rev. Cancer 1826 (2012)
443–457.
[18] N.A. Mikirova, J.J. Casciari, R.E. Hunninghake, N.H. Riordan, Intravenous
ascorbic acid protocol for cancer patients: scientiﬁc rationale, pharmacology,
and clinical experience, Funct. Foods Health Dis. 3 (8) (2013) 344–366.
[19] J.L. Welsh, B.A. Wagner, T.J. van ’t Erve, P.S. Zehr, D.J. Berg, T.R. Halfdanarson,
N.S. Yee, K.L. Bodeker, J. Du, L.J. Roberts 2nd, M. Levine, G.R. Buettner, J.J. Cullen,
Pharmacological ascorbate with gemcitabine for the control of metastatic and
node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial,
Cancer Chemother. Pharmacol. 71 (3) (2013) 765–775.
[20] Q. Chen, M.G. Espey, M.C. Krishna, J.B. Mitchell, C.P. Corpe, G.R. Buettner,
E. Shacter, M. Levine, Ascorbic acid at pharmacologic concentrations selec-
tively kills cancer cells: ascorbic acid as a pro-drug for hydrogen peroxide
delivery to tissues, Proc. Natl. Acad. Sci. USA 102 (2005) 13604–13609.
[21] Q. Chen, M.G. Espey, A.Y. Sun, J.H. Lee, M.C. Krishna, E. Shacter, P.L. Choyke,
C. Pooput, K.L. Kirk, G.R. Buettner, M. Levine, Ascorbic acid in pharmacologic
concentrations: a pro-drug for selective delivery of ascorbate radical and
hydrogen peroxide to extracellular ﬂuid in vivo, Proc. Natl. Acad. Sci. USA 104
(2007) 8749–8754.
[22] K.E. Olney, J. Du, T.J. van ‘t Erve, J.R. Witmer, Z.A. Sibenaller, B.A. Wagner, G.
R. Buettner, J.J. Cullen, Inhibitors of hydroperoxide metabolism enhance
ascorbate-induced cytotoxicity, Free Radic. Res. 47 (3) (2013) 154–163.
[23] M. Rawal, S.R. Schroeder, B.A. Wagner, C.M. Cushing, J. Welsh, A.M. Button,
J. Du, Z.A. Sibenaller, G.R. Buettner, J.J. Cullen, Manganoporphyrins increase
ascorbate-induced cytotoxicity by enhancing H2O2 generation, Cancer Res. 73
(16) (2013) 5232–5241.
Fig. 6. IR has a minor effect on the release of AscH and irradiation has an additive
effect on the amount of labile iron released in MIA PaCa-2 tumor homogenates. MIA
PaCa-2 tumors grown in nude athymic mice were homogenized in 2 mL of pH
6.5 PBS and then 1 mM DFO was added. Each homogenate was split into four
aliquots to receive four different treatments: no treatment, treatment with 15 Gy of
radiation, treatment with 10 mM AscH , or treatment with 15 Gy irradiation and
10 mM AscH . Samples (n¼3) were then analyzed for labile iron (each three
separate times) using EPR, g¼4.3 at 100 K. Both AscH and irradiation appear to
independently increase the labile iron pool, p¼0.23 and 0.19, respectfully; there is
trend that suggests an apparent additive effect with the combined treatment of
AscH and irradiation, p¼0.06. Error bars represent standard error.
J.C. Moser et al. / Redox Biology 2 (2014) 22–2726
[24] G.R. Buettner, B.A. Jurkiewicz, Catalytic metals, ascorbate, and free radicals:
combinations to avoid, Radiat. Res. 145 (1996) 532–541.
[25] P. Wardman, L.P. Candeias, Fenton chemistry: an introduction, Radiat. Res. 145
(5) (1996) 523–531.
[26] H.F. Bienfait, M.L. van den Briel, Rapid mobilization of ferritin iron by
ascorbate in the presence of oxygen, Biochim. Biophys. Acta. 631 (1980)
507–510.
[27] R.F. Boyer, C.J. McCleary, Superoxide ion as a primary reductant in ascorbate-
mediated ferritin iron release, Free Radic. Biol. Med. 3 (1987) 389–395.
[28] O. Reelfs, R.M. Tyrrell, C. Pourzand, Ultraviolet a radiation-induced immediate
iron release is a key modulator of the activation of NF-kappaB in human skin
ﬁbroblasts, J. Invest. Dermatol. 122 (2004) 1440–1447.
[29] E. Robello, A. Galatro, S. Puntarulo, Labile iron pool and ferritin content in
developing rat brain gamma-irradiated in utero, Neurotoxicology 30 (2009)
430–435.
[30] E. Pelle, J. Jian, L. Declercq, K. Dong, Q. Yang, C. Pourzand, D. Maes, N. Pernodet,
D.B. Yarosh, X. Huang, Protection against ultraviolet A-induced oxidative
damage in normal human epidermal keratinocytes under post-menopausal
conditions by an ultraviolet A-activated caged-iron chelator: a pilot study,
Photodermatol. Photoimmunol. Photomed. 27 (2011) 231–235.
[31] C.J. Koch, J.E. Biaglow, Toxicity, radiation sensitivity modiﬁcation, and meta-
bolic effects of dehydroascorbate and ascorbate in mammalian cells, J. Cell
Physiol. 94 (3) (1978) 299–306.
[32] P.M. Herst, K.W. Broadley, J.L. Harper, M.J. McConnell, Pharmacological
concentrations of ascorbate radiosensitize glioblastoma multiforme primary
cells by increasing oxidative DNA damage and inhibiting G2/M arrest, Free
Radic. Biol. Med. 52 (2012) 1486–1493.
[33] K. Shinozaki, Y. Hosokawa, M. Hazawa, I. Kashiwakura, K. Okumura, T. Kaku,
E. Nakayama, Ascorbic acid enhances radiation-induced apoptosis in an HL60
human leukemia cell line, J. Radiat. Res. 52 (2011) 229–237.
[34] G.R. Buettner, In the absence of catalytic metals, ascorbate does not autoxidize
at pH 7: ascorbate as a test for catalytic metals, J. Biochem. Biophys. Methods
16 (1988) 27–40.
[35] G.N. Ling, T. Kolebic, R. Damadian, Low paramagnetic-ion content in cancer
cells: its signiﬁcance in cancer detection by magnetic resonance imaging,
Physiol. Chem. Phys. Med. NMR 22 (1) (1990) 1–14.
[36] S.L. Baader, G. Bruchelt, T.C. Carmine, H.N. Lode, A.G. Rieth, D. Niethammer,
Ascorbic-acid-mediated iron release from cellular ferritin and its relation to
the formation of DNA strand breaks in neuroblastoma cells, J. Cancer Res. Clin.
Oncol. 120 (7) (1994) 415–421.
[37] B. Deubzer, F. Mayer, Z. Kuci, M. Niewisch, G. Merkel, R. Handgretinger,
G. Bruchelt, H2O2-mediated cytotoxicity of pharmacologic ascorbate concen-
trations to neuroblastoma cells: potential role of lactate and ferritin, Cell
Physiol. Biochem. 25 (6) (2010) 767–774.
[38] S.J. Padayatty, H. Sun, Y. Wang, H.D. Riordan, S.M. Hewitt, A. Katz, R.A. Wesley,
M. Levine, Vitamin C pharmacokinetics: implications for oral and intravenous
use, Ann. Intern. Med. 140 (7) (2004) 533–537.
[39] B.A. Wagner, J.R. Witmer, T.J. van ‘t Erve, G.R. Buettner, An assay for the rate of
removal of extracellular hydrogen peroxide by cells, Redox Biol. 1 (2013)
210–217.
J.C. Moser et al. / Redox Biology 2 (2014) 22–27 27
